Peptide Registry

Vials

Capsules

Liquids

a vial of ACE-031 1mg

ACE-031

$109.00

  • Contents: ACE-031 (ACVR2B-Fc fusion protein; Ramatercept)
  • Form: Lyophilized protein
  • Purity: >99%
Quantity Discount Price
1 - 3 - $109.00
4 - 7 10% $98.10
8 + 18% $89.38
SKU: N/A Categories: , Brand:

Description

ACE-031 is a recombinant fusion protein, not a peptide, composed of the extracellular domain of human activin receptor type IIB (ACVR2B) linked to the Fc region of human immunoglobulin G1 (IgG1). It functions as a soluble decoy receptor, circulating in biological systems and intercepting myostatin (GDF-8) and related TGF-β superfamily ligands before they can engage their native membrane-bound receptors on muscle satellite cells. Under normal physiological conditions, myostatin binding to membrane ACVR2B recruits type I receptors and initiates SMAD2/3 phosphorylation — a cascade that suppresses protein synthesis and promotes muscle atrophy. ACE-031 disrupts this cascade at the ligand level, trapping myostatin and structurally related ligands including activin A, activin B, GDF-11, BMP9, and BMP10 before receptor engagement occurs.

Chemical Information

  • Chemical Name: Activin Receptor Type IIB / IgG1-Fc fusion protein (ACVR2B-Fc)
  • Also Known As: Ramatercept; ACVR2B/Fc; ActRIIB-IgG1
  • Compound Class: Recombinant fusion protein (soluble decoy receptor)
  • Molecular Weight: ~80 kDa (homodimeric); ~58 kDa per glycosylated monomer
  • Structure: Recombinant homodimeric fusion protein; 343-amino acid monomer with N-glycosylation sites
  • Production: Mammalian cell expression system (not solid-phase peptide synthesis)

Applications

  • In vitro investigation of ACVR2B ligand-trap binding interactions within the TGF-β superfamily
  • Laboratory studies of myostatin (GDF-8) and activin A/B signaling in cell-based assay systems
  • SMAD2/3 phosphorylation pathway research in muscle satellite cell models
  • Comparative evaluation of soluble decoy receptor approaches versus antibody-based myostatin inhibition strategies
  • Structure-activity studies examining ligand selectivity across TGF-β superfamily members — ACE-031 binds myostatin, activin A/B, GDF-11, BMP9, and BMP10, making it useful for studying relative ligand affinity and pathway specificity within the same experimental model
  • Reference compound for analytical method development involving recombinant Fc fusion proteins

Storage and Handling

Store lyophilized protein at -20°C to -80°C for long-term stability. Once reconstituted, store solutions at 2–8°C and use promptly. Avoid repeated freeze-thaw cycles. Recombinant fusion proteins are susceptible to aggregation and loss of binding activity under repeated thermal cycling. Protect from light and elevated temperatures. Handle under aseptic laboratory conditions.

Note: As a large glycosylated recombinant protein, ACE-031 requires careful handling that differs from lyophilized peptide compounds. Refer to the certificate of analysis for reconstitution guidance specific to each batch.

Compliance Notice

ACE-031 is for laboratory research use only. It is not intended for human or veterinary use, and it is not formulated for clinical, diagnostic, or therapeutic applications. This product is a research-grade reagent and is not manufactured under GMP conditions. It is not equivalent to, or a substitute for, any clinical- or pharmaceutical-grade material. By purchasing this product, the buyer confirms it will be used exclusively for controlled in vitro research by qualified personnel following appropriate institutional safety procedures.

Frequently Asked Questions

What is ACE-031?

ACE-031 (Ramatercept) is a recombinant fusion protein consisting of the extracellular domain of human ACVR2B linked to an IgG1 Fc region. It functions as a soluble ligand trap — intercepting myostatin and related TGF-β superfamily ligands before they can bind to membrane-bound receptors and initiate SMAD2/3-mediated muscle atrophy signaling. It is a recombinant protein produced through mammalian cell expression, not a synthetic peptide.

How does ACE-031 differ from antibody-based myostatin inhibitors in research models?

Antibody-based myostatin inhibitors typically target myostatin specifically through antigen-antibody binding. ACE-031 acts as a decoy receptor. Its ACVR2B extracellular domain retains binding affinity for the full range of ACVR2B ligands, including activin A, activin B, GDF-11, BMP9, and BMP10 alongside myostatin. This broader ligand-trapping profile makes ACE-031 useful when the research question involves the full scope of ACVR2B pathway biology rather than myostatin-specific inhibition, but it also means experimental designs must account for off-target ligand sequestration — particularly BMP9, whose inhibition was associated with vascular safety signals in clinical development.

What happened in ACE-031 clinical development and why is it relevant to research design?

ACE-031 advanced through Phase I and early Phase II clinical investigation, including a trial in boys with Duchenne muscular dystrophy that was terminated due to adverse events including epistaxis and telangiectasias. Subsequent analysis linked these events to BMP9 inhibition — BMP9 is critical for vascular remodeling and is also a high-affinity ACVR2B ligand. For researchers using ACE-031 in laboratory models, this history is mechanistically informative: the compound's broad ligand-trapping profile extends to vascular biology pathways, which should be accounted for in study design and result interpretation.

How should ACE-031 be handled differently from peptide research compounds?

ACE-031 is a large glycosylated recombinant protein, not a synthetic peptide. Its stability is more sensitive to temperature variation, agitation, and freeze-thaw cycling than most lyophilized peptides. Reconstituted solutions should be stored at 2–8°C and used promptly rather than stored long-term. Refer to the certificate of analysis for batch-specific reconstitution guidance, as optimal buffer conditions and concentration may vary between production lots.

Related products